February 2022 • BioTech Health X

Biotech NewsCelyad Oncology Pauses CYAD-101-002 (Keynote-B79) Phase 1 Trial After 2 Deaths Reported

BioTech Health X
February 28, 2022

Clinical-stage biotechnology company Celyad Oncology (NASDAQ: CYAD) recently announced that the company has voluntarily paused the CYAD-101-002 (KEYNOTE-B79)…

Cellarity-Expands-Leadership-Team-to-Continue-Evolution-of-Breakthrough-Platform-to-Encode-Biology-and-Purposefully-Create-New-DrugsCellarity-Expands-Leadership-Team

Biotech NewsCellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs

BioTech Health X
February 10, 2022

With the appointments of these experts, the firm has added to its industry knowledge, including Chief Scientific Officer…

BioTech CEO InterviewsBioTech Health X CEO Series: Virios Therapeutics Greg Duncan

BioTech Health X
February 1, 2022

BioTech Health X works to deliver the latest coverage and updates in the biotechnology sector. This includes providing…

Month: February 2022

Biotech NewsCelyad Oncology Pauses CYAD-101-002 (Keynote-B79) Phase 1 Trial After 2 Deaths Reported

Biotech NewsCellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs

BioTech CEO InterviewsBioTech Health X CEO Series: Virios Therapeutics Greg Duncan

Johnson & Johnson (JNJ) Flexes Its Oncology Muscle With 16.4% Sales Growth

Would You Still Dare to Invest in Revolution Medicines (RVMD)?

Merck (MRK) Has an $8.6 Billion Cancer Franchise and a Succession Plan to Prove

AbbVie (ABBV) Delivers $17.4 Billion in Revenue

Pfizer (PFE) Gets an Oncology Boost as Padcev Sales Surge 55%

Guardant Health (GH) Posts 44% Revenue Growth as Liquid Biopsy Gains Ground

Natera (NTRA) Gets a Growth Spurt as Cancer Testing Volume Jumps 57%

Is it Still a Wise Move to Invest in Cogent Biosciences (COGT)?

Hello, I’m
BioTech Health X

Subscribe toOur Updates

Subscribe to
Our Updates